ventricular action potential
Recently Published Documents


TOTAL DOCUMENTS

130
(FIVE YEARS 12)

H-INDEX

28
(FIVE YEARS 2)

Channels ◽  
2021 ◽  
Vol 15 (1) ◽  
pp. 465-482
Author(s):  
Ahmet Kürşad Sırcan ◽  
Sevgi Şengül Ayan

Author(s):  
Giulia Guidi ◽  
Chiara Bartolucci ◽  
Anthony Frosio ◽  
Procolo Marchese ◽  
Annalisa Bucchi ◽  
...  

2020 ◽  
Vol 886 ◽  
pp. 173542
Author(s):  
Marguerite Le Marois ◽  
Véronique Ballet ◽  
Camille Sanson ◽  
Magali-Anne Maizières ◽  
Thierry Carriot ◽  
...  

2020 ◽  
Vol 49 (5) ◽  
pp. 323-342
Author(s):  
Sevgi Şengül Ayan ◽  
Ahmet K. Sırcan ◽  
Mohamedou Abewa ◽  
Ahmet Kurt ◽  
Uğur Dalaman ◽  
...  

eLife ◽  
2020 ◽  
Vol 9 ◽  
Author(s):  
Briana M Bohannon ◽  
Alicia de la Cruz ◽  
Xiaoan Wu ◽  
Jessica J Jowais ◽  
Marta E Perez ◽  
...  

The cardiac ventricular action potential depends on several voltage-gated ion channels, including NaV, CaV, and KV channels. Mutations in these channels can cause Long QT Syndrome (LQTS) which increases the risk for ventricular fibrillation and sudden cardiac death. Polyunsaturated fatty acids (PUFAs) have emerged as potential therapeutics for LQTS because they are modulators of voltage-gated ion channels. Here we demonstrate that PUFA analogues vary in their selectivity for human voltage-gated ion channels involved in the ventricular action potential. The effects of specific PUFA analogues range from selective for a specific ion channel to broadly modulating cardiac ion channels from all three families (NaV, CaV, and KV). In addition, a PUFA analogue selective for the cardiac IKs channel (Kv7.1/KCNE1) is effective in shortening the cardiac action potential in human-induced pluripotent stem cell-derived cardiomyocytes. Our data suggest that PUFA analogues could potentially be developed as therapeutics for LQTS and cardiac arrhythmia.


Sign in / Sign up

Export Citation Format

Share Document